China Approves Sinovac Vaccine for Children Aged Three and Up

The head of Chinese biotech company Sinovac, Yin Weidong, stated in an interview with state television that China has approved the emergency use of the vaccine produced by the company to prevent COVID-19 for the age group of three to 17 years old. Vaccination campaigns in China, which have administered over 723 million doses as of June 3, continue to refuse to provide vaccines to those under 18. Yin added in a live interview with Chinese television that the availability of the vaccine for younger age groups depends on health authorities developing vaccination strategies. Phase one and two clinical trials of the vaccine have shown that it stimulates the immune system in children aged three to teenagers aged 17.